EODData

MEMBERSHIP REGISTER LOG IN

FRA, 8ZD: ABBISKO CAYMAN DL-00001

02 Oct 2025
LAST:

1.910

CHANGE:
 0.05		OPEN:
1.920		HIGH:
1.920		ASK:
0.000		VOLUME:
7K
CHG(%):
2.69		PREV:
1.860		LOW:
1.910		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Oct 251.9201.9201.9101.9107K
01 Oct 251.8601.8601.8601.8600
30 Sep 251.9101.9201.9101.9100
29 Sep 251.8801.8801.8601.8607K
26 Sep 251.8301.8301.8101.8107K
25 Sep 251.8601.8601.8401.8407K
24 Sep 251.8601.8601.8501.8507K
23 Sep 251.8901.9101.8901.9107K
22 Sep 251.8801.8901.8801.8807K
19 Sep 251.8301.8401.8301.830500

COMPANY PROFILE

Name:ABBISKO CAYMAN DL-00001
About:Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; and Irpagratinib (ABSK011), a small molecule inhibitor of FGFR4 for the treatment of advanced hepatocellular carcinoma. In addition, the company develops products in Phase Ib/II trial, such as Fexagratinib (ABSK091) for the treatment of urothelial carcinoma; ABSK061, a small molecule inhibitor targeting FGFR 2/3 to treat solid tumors and achondroplasia; and ABSK043, a PD-L1 inhibitor for the treatment of non-small cells lung cancer (NSCLC). Further, it is developing products in Phase I/Ia trial comprising ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3 to treat solid tumors; ABSK112, an EGFR Exon20ins inhibitor for the treatment of NSCLC; and ABSK051, a small molecule CD73 inhibitor to treat various tumor types, such as lung and pancreatic cancer, as well as IND-stage trial products, including ABSK012, a small molecule FGFR4 inhibitor for treatment of rhabdomyosarcoma, advanced solid tumors, and soft tissue sarcoma; ABK3376, an EGFR inhibitor to treat NSCLC harboring the EGFR-C797S mutation; and ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor for the treatment of solid tumors. Additionally, the company's pre-clinical pipeline products comprise P017, P018, ASBK141, P021, P019, and P020 to treat solid tumors; and P151 for non-oncology indications. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:Building 3, Shanghai, China
Website:https://www.abbisko.com
ISIN:KYG0028A1085

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:64.00
Price to Book:4.46
Price to Sales:2.16
EBITDA:96.02M
Shares:659.75M
Market Cap:1.26B

TECHNICAL INDICATORS

MA5:1.87
MA10:1.87
MA20:1.87
MA50:1.67
MA100:1.36
MA200:1.04
STO9:90.91
STO14:93.33
RSI14:48.33
ATR:0.05
Week High:1.92
Week Low:1.81
Month High:1.97
Month Low:1.77
Year High:1.97
Year Low:0.36
Volatility:63.06